On May 22, 2017 IPHARMA received the Ministry of Health permission to conduct clinical trial of Phase I of the drug XC221.
Protocol #ARI-XC221-01 "Double-blind randomized placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of increasing doses of the drug XC221 for single and subsequent oral administration in healthy volunteers."
The purpose of the clinical trial is the evaluation of the safety profile and tolerability of the drug XC221 in a single and subsequent multiple admission in healthy volunteers.
The leading organization in conducting the study is I.M.Sechenov First Moscow State Medical University.
The drug developer is Phamenterprises LLC. Pharmenterprises specialized in developing innovative anticontagious drugs.